Antibiotic monensin synergizes with EGFR inhibitors and oxaliplatin to suppress the proliferation of human ovarian cancer cells

Ovarian cancer is the most lethal gynecologic malignancy with an overall cure rate of merely 30%. Most patients experience recurrence within 12–24 months of cure and die of progressively chemotherapy-resistant disease. Thus, more effective anti-ovarian cancer therapies are needed. Here, we investiga...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Youlin, Zhang, Junhui, Wang, Zhongliang, Yan, Zhengjian, Qiao, Min, Ye, Jixing, Wei, Qiang, Wang, Jing, Wang, Xin, Zhao, Lianggong, Lu, Shun, Tang, Shengli, Mohammed, Maryam K., Liu, Hao, Fan, Jiaming, Zhang, Fugui, Zou, Yulong, Liao, Junyi, Qi, Hongbo, Haydon, Rex C., Luu, Hue H., He, Tong-Chuan, Tang, Liangdan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671000/
https://www.ncbi.nlm.nih.gov/pubmed/26639992
http://dx.doi.org/10.1038/srep17523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671000/
https://www.ncbi.nlm.nih.gov/pubmed/26639992
http://dx.doi.org/10.1038/srep17523

Ejemplares similares